Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial (Q46985882)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 2006

Language	Label	Description	Also known as
English	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial	scientific article published in March 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

0 references

0 references

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

Valerio De Stefano

14

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Giovannino Ciccone

19

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Pellegrino Musto

21

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Manuela Ceccarelli

15

object named as

Manuela Ceccarelli

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Antonio Palumbo

1

object named as

Antonio Palumbo

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

author name string

Sara Bringhen

2

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Tommaso Caravita

3

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Emanuela Merla

4

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Vincenzo Capparella

5

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Vincenzo Callea

6

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Clotilde Cangialosi

7

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Mariella Grasso

8

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Fausto Rossini

9

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Monica Galli

10

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Lucio Catalano

11

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Elena Zamagni

12

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Maria Teresa Petrucci

13

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Maria Teresa Ambrosini

16

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Ilaria Avonto

17

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Patrizia Falco

18

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Anna Marina Liberati

20

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Mario Boccadoro

22

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Italian Multiple Myeloma Network, GIMEMA

23

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

language of work or name

0 references

publication date

1 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

367

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

9513

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

825-831

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Deep venous thrombosis and thalidomide therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer and venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose thalidomide in myeloma: efficacy and biologic significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968338-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(06)68338-4

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16530576

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46985882&oldid=2140926948"